ATTBF — Abattis Bioceuticals Share Price
Last Trade - 00:00- $5.21m
- $3.10m
- CA$0.36m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 30th Sep | Unit | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 0.09 | n/a | n/a | 0.01 | 0.36 | n/a | n/a | 115.27% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Abattis Bioceuticals Corp. is a Canada-based specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The Company, through its subsidiaries, develops and commercializes natural health (nutraceutical) products, and conducts research and development to create plant-based (botanical) intellectual property and ingredients for the pharmaceutical and bioceutical markets, among others. It offers products and services, such as botanical blends and formulas; cannabidiol ingredients; functional foods and beverages, and analytical services. It is focused on creating botanical formulations, medical marijuana and specialized health products for pain caused by inflammation, and mental ailments.
Directors
- Last Annual
- September 30th, 2019
- Last Interim
- September 30th, 2019
- Incorporated
- June 30th, 1997
- Public Since
- December 23rd, 2010
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 477,804,139
- Address
- 1200 - 625 Howe Street, VANCOUVER, V6C 2T6
- Web
- https://abattis.com/
- Phone
- +1 6042297911
- Auditors
- NVS Chartered Accountants
Upcoming events for ATTBF
Similar to ATTBF
4CABLE TV INTERNATIONAL ORD
Pink Sheets on Nasdaq
AIMTC ORD
Pink Sheets on Nasdaq
AMERICAN CARESOURCE ORD
Pink Sheets on Nasdaq
AMERICAN MOBILE DENTAL ORD
Pink Sheets on Nasdaq
AMERICANN ORD
Pink Sheets on Nasdaq
FAQ
As of Today at 11:30 UTC, shares in Abattis Bioceuticals are trading at $0.01. This share price information is delayed by 15 minutes.
Shares in Abattis Bioceuticals last closed at $0.01 and the price had moved by +51.39% over the past 365 days. In terms of relative price strength the Abattis Bioceuticals share price has outperformed the S&P500 Index by +17.11% over the past year.
There is no consensus recommendation for this security.
Abattis Bioceuticals does not currently pay a dividend.
Abattis Bioceuticals does not currently pay a dividend.
Abattis Bioceuticals does not currently pay a dividend.
To buy shares in Abattis Bioceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.01, shares in Abattis Bioceuticals had a market capitalisation of $5.21m.
Here are the trading details for Abattis Bioceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ATTBF
Based on an overall assessment of its quality, value and momentum Abattis Bioceuticals is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Abattis Bioceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -56.05%.
As of the last closing price of $0.01, shares in Abattis Bioceuticals were trading -28.83% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Abattis Bioceuticals.
We do not have data on Abattis Bioceuticals' directors
We do not have data on Abattis Bioceuticals' shareholders